Berro Y Cebolla

Description

Berro y cebolla DM is a pharmaceutical formulation that combines the active ingredients of watercress (Berro) and onion (Cebolla). The product is designed for therapeutic use, leveraging the properties of its botanical components. The specific molecular weight and chemical formula are not provided. The dosage form and appearance of the product are also unspecified, indicating a need for further detail in professional labeling.

Uses and Indications

This drug is indicated for the temporary relief of cough associated with the common cold. It also aids in loosening phlegm (mucus) and thinning bronchial secretions, facilitating the clearance of bothersome mucus from the bronchial passageways.

Limitations of Use: This medication is intended for symptomatic relief and does not address the underlying causes of cough or cold symptoms.

Dosage and Administration

The medication should be shaken well before use to ensure proper mixing of the formulation.

For adults and children aged 12 years and older, the recommended dosage is 2 tablespoons (30 mL) every 4 hours. For children aged 6 to under 12 years, the dosage is 1 tablespoon (15 mL) every 4 hours.

It is important to note that no more than 6 doses should be administered within a 24-hour period, unless otherwise directed by a healthcare professional. For children under 6 years of age, consultation with a doctor is advised prior to administration.

Contraindications

There are no specific contraindications listed for this product. However, healthcare professionals should advise patients to discontinue use and consult a physician if the following conditions arise:

• Cough persists for more than one week, recurs, or is accompanied by fever, rash, or persistent headache, as these may indicate a serious underlying condition.

• Symptoms of nervousness, dizziness, or sleeplessness occur, which may warrant further evaluation.

Warnings and Precautions

The use of this product is contraindicated in individuals currently taking a prescription monoamine oxidase inhibitor (MAOI), which includes certain medications prescribed for depression, psychiatric or emotional conditions, or Parkinson's disease. Additionally, it should not be used for a period of two weeks following the discontinuation of an MAOI. Healthcare professionals are advised to confirm whether a patient’s prescription includes an MAOI by consulting with the patient or their pharmacist prior to recommending this product.

Healthcare providers should exercise caution and advise patients to seek medical consultation before using this product if they have a persistent or chronic cough, a cough accompanied by excessive phlegm (mucus), or any breathing issues such as those associated with smoking, asthma, chronic bronchitis, or emphysema.

In the event of an accidental overdose, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Patients should be instructed to discontinue use and consult a healthcare professional if any of the following occur: a cough that persists for more than one week, a cough that tends to recur, or if it is accompanied by fever, rash, or a persistent headache, as these may indicate a serious underlying condition. Additionally, if symptoms such as nervousness, dizziness, or sleeplessness arise, patients should stop taking the product and seek medical advice.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious adverse reactions may occur, and it is crucial to adhere to the recommended dosage to avoid complications. Patients are advised not to use this medication if they are currently taking a prescription monoamine oxidase inhibitor (MAOI) or have stopped taking an MAOI drug within the past two weeks, as this combination may lead to serious interactions.

Common adverse reactions include nervousness, dizziness, and sleeplessness. If any of these symptoms occur, patients should discontinue use and consult a healthcare professional. Additionally, patients should seek medical advice if a cough persists for more than one week, recurs, or is accompanied by fever, rash, or a persistent headache, as these may indicate a serious underlying condition.

Patients with a persistent or chronic cough, excessive phlegm, or pre-existing breathing problems such as those associated with smoking, asthma, chronic bronchitis, or emphysema should consult a healthcare provider before using this medication to ensure safety and appropriateness of treatment.

Drug Interactions

The concomitant use of this product with prescription monoamine oxidase inhibitors (MAOIs) is contraindicated. MAOIs are typically prescribed for the treatment of depression, psychiatric or emotional conditions, and Parkinson's disease. Patients should not take this product while on MAOIs or for a minimum of two weeks following the discontinuation of an MAOI.

It is essential for patients to consult with a healthcare professional, such as a doctor or pharmacist, to verify whether their current prescription includes an MAOI before initiating treatment with this product.

Packaging & NDC

Below are the non-prescription pack sizes of Berro Y Cebolla (dextromethorphan hydrobromide, guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 6 years of age should consult a doctor before use. For children aged 6 to under 12 years, the recommended dosage is 1 tablespoon (15 mL) every 4 hours. In contrast, adults and children 12 years of age and older may take 2 tablespoons (30 mL) every 4 hours. It is important for healthcare professionals to consider these age-specific dosing recommendations when prescribing this medication to ensure safety and efficacy in pediatric populations.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure the safety of both the mother and the developing fetus or nursing infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients to ensure safety and efficacy.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor patients closely for any signs or symptoms that may arise following an overdose. Common symptoms may include, but are not limited to, altered mental status, cardiovascular instability, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Supportive care is the cornerstone of management, which may involve the following steps:

1. Assessment: Conduct a thorough evaluation of the patient's clinical status, including vital signs and level of consciousness.

2. Supportive Care: Provide symptomatic treatment as necessary, which may include intravenous fluids, oxygen supplementation, and monitoring of cardiac function.

3. Decontamination: If the overdose is recent and the patient is alert, activated charcoal may be considered to limit further absorption of the substance.

4. Consultation: Engage with a poison control center or toxicology specialist for guidance on specific antidotes or advanced interventions, if applicable.

Healthcare professionals should remain vigilant and prepared to implement these management strategies in the event of an overdose, despite the lack of specific information regarding the substance in question.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center in the event of an accidental overdose.

Patients should be instructed to discontinue use and consult a doctor if their cough persists for more than one week, recurs, or is accompanied by symptoms such as fever, rash, or a persistent headache, as these may indicate a serious underlying condition.

Additionally, healthcare providers should inform patients to stop using the medication and seek medical advice if they experience nervousness, dizziness, or sleeplessness.

It is important for patients to consult a doctor before using the medication if they have a persistent or chronic cough, or if their cough is accompanied by excessive phlegm (mucus).

Patients with pre-existing breathing problems, such as those associated with smoking, asthma, chronic bronchitis, or emphysema, should also be advised to seek medical guidance prior to use.

Storage and Handling

This product is supplied in configurations that include specific NDC numbers, which should be referenced for accurate identification. It is essential to store the product within a temperature range of 15° to 30° C (59° to 86° F) to maintain its integrity and efficacy.

Healthcare professionals are advised to inspect the product prior to use; it should not be utilized if the printed safety seal over the cap is torn, broken, or missing, as this may indicate potential tampering or contamination. Proper handling and storage conditions are crucial to ensure the product remains safe and effective for patient use.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Berro Y Cebolla, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)